Crescendo Biologics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Crescendo Biologics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10869
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company’s pipeline includes humabody programs targeting oncology. It practises in the antibody discoveries and development, which include CAT, medimmune, morphosys and GSK. Crescendo develops a transformational Humabody-based topical biologic for psoriasis, which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The company’s oncology programmes produce novel therapeutics that capitalizes on advantages of the Humabody VH format. Crescendo is headquartered in Cambridge, the UK.

Crescendo Biologics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 12
Crescendo Biologics Raises US$3.3 Million In Series A Financing 13
Crescendo Biologics Raises US$28 Million In Series A Financing 14
Licensing Agreements 16
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 16
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 17
Crescendo Biologics Ltd – Key Competitors 18
Crescendo Biologics Ltd – Key Employees 19
Crescendo Biologics Ltd – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Jun 14, 2017: Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer 21
Apr 03, 2017: Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer 22
Other Significant Developments 23
Aug 15, 2018: Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 10
Crescendo Biologics Raises Funds through Venture Financing 12
Crescendo Biologics Raises US$3.3 Million In Series A Financing 13
Crescendo Biologics Raises US$28 Million In Series A Financing 14
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 16
Zai Lab Enters into Licensing Agreement with Crescendo Biologics 17
Crescendo Biologics Ltd, Key Competitors 18
Crescendo Biologics Ltd, Key Employees 19

List of Figures
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crescendo Biologics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Crescendo Biologics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CSM nv:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' CSM nv Mergers and Acquisitions …
  • Japan Pulp and Paper Co Ltd:戦略・SWOT・企業財務分析
    Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Pulp and Paper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Profire Energy, Inc (PFIE):企業のM&A・提携動向(石油・ガス分野)
    Summary Profire Energy, Inc (Profire Energy) is an oilfield technology company that undertakes design, development and installation of combustion management technology products for oil and gas industries. The company provides burner management systems; chemical management systems; components for a w …
  • Verde Science Inc. (VRCI):企業の財務及び戦略的SWOT分析
    Summary Verde Science Inc. (Verde Science) is a medical technology company that provides bioprocess solutions. The company offers research and development services with expertise in bioprocess technology, nanotechnology, molecular virology and immunology, pharmacology and medical device design. Its …
  • Galderma S.A.:企業のM&A・提携動向(医療機器分野)
    Summary Galderma S.A. (Galderma) is a pharmaceutical company. It develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. The company products include arcolan, azzalure, benzac, calmurid, capex, cetaphil, clindag …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Compass Group PLC:企業の戦略・SWOT・財務分析
    SummaryCompass Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • The Tokyo Tomin Bank, Limited:企業の戦略・SWOT・財務分析
    SummaryThe Tokyo Tomin Bank, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the compan …
  • Integrated Device Technology Inc.:企業のM&A・提携・投資分析
    Integrated Device Technology Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Integrated Device Technology Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • New Britain Palm Oil Limited:企業の戦略・SWOT・財務分析
    SummaryNew Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company …
  • Silicom Ltd. (SILC):企業の財務及び戦略的SWOT分析
    Summary Silicom Ltd. (Silicom) is a provider of networking and data infrastructure solutions. The company designs, manufactures and markets connectivity solutions. It offers networking adapters, networking bypass adapters, time stamping adapters and capturing, networking intelligent adapters, encryp …
  • InterOil Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' InterOil Corporation Mergers an …
  • Egmont International Holding A/S:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Egmont International Holding A/ …
  • PRAMAC S.p.A.の企業概要及び財務/SWOT分析
    PRAMAC S.p.A. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecas …
  • Orano SA:電力:M&Aディール及び事業提携情報
    Summary Orano SA (Orano), formerly New AREVA Holding, is an integrated nuclear energy company that transforms nuclear materials and provides technological solutions for power generation and allied services. It offers complete range of products and services that covers the entire nuclear fuel cycle r …
  • Smruthi Organics Ltd (590046):企業財務及び戦略的SWOT分析
    Summary Smruthi Organics Ltd (Smruthi) is a manufacturer and distributor of bulk drugs, drug intermediates, fine chemicals and specialty chemicals. The company offers products which include amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydroch …
  • Guangxi Yuchai Machinery Company Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Guangxi Yuchai Machinery Compan …
  • Cpp Group Plc (CPP):企業概要、財務及び戦略的SWOT分析
    Summary Cpp Group Plc (CPP) is a financial services provider. The company is an international life assistance business operator. Its products include as card protection, identity safe, phonesafe, packaged accounts, home 3, travel assistance, purchase shield, legal protection and airport angel. CPP’s …
  • Peninsula Minerals Limited (PEN):企業概要、財務及び戦略的SWOT分析
    Summary Peninsula Minerals Limited (PEN) is a mineral exploration company. The company acquires, develops and explores uranium assets in Wyoming, the US and Karoo, South Africa. Its projects include Lance project, Karoo and RAKI RAKI gold project. PEN’s Lance project is located on the North-East fla …
  • Richard Wolf GmbH:企業の戦略的SWOT分析
    Richard Wolf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆